Drugs / HB-110
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01641536 | Nov 2011 → Dec 2012 | chronic hepatitis B virus infection | Genexine, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00513968 | Jul 2007 → Apr 2010 | chronic hepatitis B virus infection | Genexine, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HB-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01641536 ↗ |
| Modality | Vaccine | “HBV DNA Vaccine” NCT00513968 ↗ |
| Route | Intramuscular | “HB-110 2mg (or 4mg or 8mg), im” NCT00513968 ↗ |